Coremend45mg
Blend of KPV, BPC-157, TB-500 (TB4)
Coremend Blend Canada — 45 mg Lyophilized Vials
TB-500 / BPC-157 / KPV Recovery Blend
Also known as CoreMend
Coremend is a research blend combining TB-500 (thymosin beta-4 fragment), BPC-157, and the tripeptide KPV in a single preparation, studied for converging tissue-repair and inflammatory-signaling pathways.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Coremend is a research blend combining TB-500 (thymosin beta-4 fragment), BPC-157, and the tripeptide KPV in a single preparation, studied for converging tissue-repair and inflammatory-signaling pathways.
Each component is independently characterized in the laboratory literature; the blend is studied as a combined preparation.
Coremend combines three research peptides associated with structural-repair and inflammatory-modulation pathways: TB-500 (cellular migration and actin regulation), BPC-157 (angiogenic and cytoprotective signaling), and KPV (anti-inflammatory α-MSH-fragment activity). Research framing draws on the established literature for each component.
The blend is studied as a combined preparation in tissue-repair research models under structured conditions.
Coremend is formulated from three independently studied research peptides. Its components — TB-500, BPC-157, and KPV — each have distinct research lineages in structural-repair and inflammatory-signaling models.
Research framing for Coremend draws on the combined literature of its components across cellular-migration, angiogenic, cytoprotective, and anti-inflammatory pathway models under controlled conditions.
0 of the 4 areas below are addressed directly by a paper cited on this page.
No paper cited on this page reports on cytoskeletal, cellular or migration. This heading marks where Coremend Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on angiogenic or cytoprotective. This heading marks where Coremend Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on anti, inflammatory or fragment. This heading marks where Coremend Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on combined, tissue or repair. This heading marks where Coremend Blend is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 1993 and 2017 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Coremend Blend, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Coremend Blend is also referred to as coremend blend, and technically as CoreMend.
Coremend Blend is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under cytoskeletal and cellular-migration models (TB-500), angiogenic and cytoprotective signaling (BPC-157) and anti-inflammatory α-MSH-fragment research (KPV).
The 3 papers cited on this page, published between 1993 and 2017 (1 review) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
The lot code printed on the vial matches the code on the certificate for Coremend Blend. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Coremend Blend in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
Coremend Blend is a co-lyophilized blend — more than one compound freeze-dried together in a single vial. Handling follows the least stable component rather than an average, and the same is true of storage: the constraint that binds is whichever compound in the vial is most sensitive.
Reconstituting a blend does not separate its components, so a blend cannot be split into its parts after the fact. That is why per-component content verification matters more here than a single blended purity figure — the ratio inside the vial is fixed at manufacture and cannot be corrected downstream.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of coremend. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Thymosin beta4 accelerates wound healing. J Invest Dermatol 113(3):364–368.
PubMedA new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris 87(5):313–327.
PubMedOrally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Out of stockPeptides
Long-Acting Amylin Analogue · 5 & 10 mg Cagrilintide is a synthetic peptide developed for controlled laboratory research involving amylin receptor signaling systems. It is structurally designed to interact with amylin-associated pathways within experimental environments.
CAG-CA-26A-0199.446%
5.62 mg / 5 mg
$69.95CAD
